Tirzepatide for heart failure, systolic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 31 Jul 2026: Trial registered, NCT07738276

The trials

NCT07738276: Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

State
Not started
Phase
Phase 3
People
60 planned
Started
18 Jul 2026
Primary completion
11 Jun 2027
Arms
Tirzepatide
Results
None posted
  1. 31 Jul 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Also known as Arm 5- Tirzepatide, Mounjaro, Tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.), Zepbound.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.